Is contrast-enhanced mammography (CEM) an alternative to MRI in assessing the response to primary systemic therapy of breast cancer?

PURPOSE: To evaluate the accuracy of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) in the assessing radiological response to primary systemic therapy (PST). METHOD: Prospective study between February 2021 and October 2022. Women with breast cancer and indication of PST were enrolled. CEM and MRI were performed before and after PST, and the findings, including size and radiological response pattern, were compared with the size of the residual lesion measured in surgical specimens and its Miller-Payne classification (considered the gold standard). Two of four independent radiologists, with 2 years of CEM experience and 10 years of MRI experience, reviewed the images while being blinded to the results of the other technique. The agreement between measurements was evaluated using the Pearson correlation coefficient (r) and Lin's coefficient. RESULTS: Forty-eight women with breast cancer who required PST were enrolled in the study, with a mean age of 57.21 ± 10.14 years. A total of thirty-three participants (68.75 %) completed the study. The correlation between CEM and MRI measurements was high before PST (r: 0.97), and local staging was identical for 45 out of 48 patients. MRI demonstrated better accuracy in predicting residual tumor size than CEM, with Lin's coefficient 0.91 and 0.73, respectively. However, no significant differences were observed in predicting response to therapy. Both methods tended to overestimate the size and degree of response in our study, with mean overestimations of 2.87 mm in CEM and 0.51 mm in MRI. CONCLUSION: CEM was found to be as accurate as MRI in predicting response to PST, indicating its potential as an alternative imaging technique, but further research is necessary.

Predicción del resultado del test Oncotype DX con RM mamaria de 1.5T en tumores con receptores hormonales positivos y HER2 negativo / Prediction of the Oncotype DX test result with 1.5T breast MRI in estrogen receptor-positive HER2-negative tumours

Objetivo Evaluar la relación del resultado del test Oncotype DX en tumores luminales con el valor del coeficiente de difusión aparente (CDA) en la secuencia de difusión en resonancia magnética (RM) mamaria y con otros parámetros radiológicos y anatomopatológicos. Pacientes y método Se revisaron retrospectivamente las RM mamarias de estadificación de las pacientes con cáncer de mama (CM) con receptores de estrógenos (RE) positivos y HER2 negativo a las que se les había solicitado el test Oncotype DX en los últimos cuatro años. Se recogieron los antecedentes familiares y personales, el tamaño y tipo de realce de la lesión, el CDA, el porcentaje de restricción a la difusión y la anatomía patológica. Todo ello se relacionó con el riesgo de recidiva (bajo: < 18, intermedio: 18-30 y alto: > 30) estimado en el test Oncotype DX. Resultados Se incluyeron 70 pacientes. Las lesiones categorizadas como bajo riesgo de recidiva asociaron valores de CDA significativamente más altos que el resto de grupos (p = 0,04) y las clasificadas como alto riesgo menor expresión de receptores de progesterona (RP) (p = 0,038). El valor de CDA clasificó como riesgo bajo o intermedio-alto según Oncotype DX con un área bajo la curva (AUC) de 0,73 (p = 0,001) para todos los tumores y de 0,76 (p < 0,001) en lesiones con RP positivos. Conclusiones Se encontraron valores más altos del CDA en el grupo clasificado como riesgo bajo de recidiva y menor expresión de RP en el grupo de riesgo alto. El CDA podría ser útil en el pronóstico del CM, aunque son necesarios más estudios. (AU)

Objective To assess the relationship of the Oncotype DX test result with the apparent diffusion coefficient (ADC) value in the diffusion sequence in breast magnetic resonance imaging (MRI) and with other radiological and anatomical-pathological parameters. Patients and methods We reviewed the pre-surgical staging breast MRIs of breast cancer (BC) patients with positive oestrogen receptors (ER) and negative HER2, for which the Oncotype DX test had been requested over the last four years. The ADC and the diffusion restriction percentage were obtained. Personal and family background were collected, along with pathological anatomy findings. We determined the association between all these factors and the risk of recurrence (low: < 18, intermediate: 18-30 and high: > 30) estimated by the Oncotype DX test. Results A total of 70 patients were included. Lesions categorized as being at low risk of recurrence according to the Oncotype DX test were associated with significantly higher ADC values than the rest of the groups (p = 0.04), and those classified as high risk were associated with lower progesterone receptor (PR) expression (p = 0.038). The ADC value classified the risk as low or intermediate-high according to the Oncotype DX test with an area under the curve (AUC) of 0.73 (p = 0.001) for all tumours and 0.76 (p < 0.001) in lesions with positive PR. Conclusions Higher ADC values were found in the group classified as being at low risk of tumour recurrence according to Oncotype DX. Lesions with high risk scores expressed lower PR. The ADC value may be useful in the prognosis of breast cancer, although further studies are required. (AU)

Radioterapia intraoperatoria en cáncer de mama precoz: análisis observacional frente a radioterapia externa / Intraoperative radiotherapy in early breast cancer: observational comparison with whole breast radiotherapy

INTRODUCCIÓN: Una única dosis de radioterapia intraoperatoria (IORT) en cáncer de mama precoz (EBC) puede ser una opción frente a la radioterapia externa estándar (WBRT). Sin embargo, no existe consenso sobre su uso y resultados. OBJETIVO: Analizar la morbilidad y resultados oncológicos de la IORT como monoterapia en el tratamiento del EBC. MÉTODOS: Se realiza un estudio analítico observacional unicéntrico, comparando una cohorte prospectiva IORT (2015-17) con una cohorte retrospectiva WBRT (2012-17). Los criterios de selección aplicados son: ≥ 45 años de edad, carcinoma ductal infiltrante o variantes, tamaño tumoral radiológico ≤ 3 cm, receptores estrogénicos positivos, HER2 negativo, cN0; criterios de exclusión: invasión linfovascular, multicentricidad/multifocalidad, mutaciones BRCA y tratamiento neoadyuvante. Se valoran características clínicas, tumorales, quirúrgicas, oncológicas y complicaciones. RESULTADOS: Se estudiaron 425 casos: 217 tratados con IORT y 208 con WBRT. La edad media en IORT y WBRT fue 67 ± 9,5 y 64,8 ± 9,9 años, respectivamente (p = 0,01). El riesgo ASA 3 en IORT fue 17,7%, frente a 24 casos de WBRT (p = 0,027). No hubo diferencias en resultados anatomopatológicos o estadificación. El seguimiento medio de IORT fue 24,4 ± 8 meses, frente a 50,5 ± 18 meses de WBRT (p < 0,001). No se hallaron diferencias significativas en recidiva local, metástasis o mortalidad. Las complicaciones que precisaron reintervención u hospitalización resultaron equiparables. La radiodermitis precoz grave se presentó en tres casos IORT frente a 14 casos WBRT (p = 0,01). CONCLUSIONES: La IORT como monoterapia en pacientes seleccionadas con EBC representa una opción alternativa frente a WBRT, especialmente en aquellas con edad avanzada y comorbilidades. Se asocia, además, con menos radiodermitis precoz grave

INTRODUCTION: In early breast cancer (EBC), a single dose of intraoperative radiotherapy (IORT) might be an option to standard whole breast radiotherapy (WBRT). However, there is no consensus about its use and clinical results. AIM: to analyse the morbidity and oncological outcomes of IORT as monotherapy in EBC. METHODS: A single centre observational analytic study was performed. A prospective IORT cohort (2015-17) and a retrospective WBRT cohort (2012-17) were selected following the same criteria: ≥ 45 y.o., invasive ductal carcinoma or variants, radiological tumour size ≤ 3 cm, positive oestrogenic receptors, negative HER2, cN0; exclusion criteria: lymphovascular invasion, multicentricity/multifocality, BRCA mutation and neoadjuvant therapy. Clinical, histological, surgical, oncological characteristics and complications were collected. RESULTS: A total of 425 cases were selected: 217 in IORT cohort and 208 in WBRT cohort. Average age in IORT and WBRT groups was 67±9.5 and 64.8 ± 9.9 y.o. respectively (p = 0.01). ASA 3 risk score patients were 17.7% in IORT and 24 cases in WBRT (p = 0.027). There were no differences in histological results or tumoral stage. Average follow up was 24.4 ± 8 months in IORT and 50.5 ± 18 months in WBRT (p < 0.001). No differences were detected in local recurrence, metastases or mortality. Complications that required reintervention or hospitalization were similar in both groups. A total of 3 and 14 cases developed early severe dermatitis in IORT and WBRT groups respectively (p = 0.01). CONCLUSION: IORT as monotherapy in selected patients with EBC stands for an alternative option versus WBRT. It seems especially useful in advanced-age patients with severe comorbidities. IORT associates lesser early severe dermatitis

Intraoperative radiotherapy in early breast cancer: observational comparison with whole breast radiotherapy. / Radioterapia intraoperatoria en cáncer de mama precoz: análisis observacional frente a radioterapia externa.

INTRODUCTION: In early breast cancer (EBC), a single dose of intraoperative radiotherapy (IORT) might be an option to standard whole breast radiotherapy (WBRT). However, there is no consensus about its use and clinical results. AIM: to analyse the morbidity and oncological outcomes of IORT as monotherapy in EBC. METHODS: A single centre observational analytic study was performed. A prospective IORT cohort (2015-17) and a retrospective WBRT cohort (2012-17) were selected following the same criteria: ≥ 45 y.o., invasive ductal carcinoma or variants, radiological tumour size ≤ 3 cm, positive oestrogenic receptors, negative HER2, cN0; exclusion criteria: lymphovascular invasion, multicentricity/multifocality, BRCA mutation and neoadjuvant therapy. Clinical, histological, surgical, oncological characteristics and complications were collected. RESULTS: A total of 425 cases were selected: 217 in IORT cohort and 208 in WBRT cohort. Average age in IORT and WBRT groups was 67±9.5 and 64.8 ± 9.9 y.o. respectively (p = 0.01). ASA 3 risk score patients were 17.7% in IORT and 24 cases in WBRT (p = 0.027). There were no differences in histological results or tumoral stage. Average follow up was 24.4 ± 8 months in IORT and 50.5 ± 18 months in WBRT (p < 0.001). No differences were detected in local recurrence, metastases or mortality. Complications that required reintervention or hospitalization were similar in both groups. A total of 3 and 14 cases developed early severe dermatitis in IORT and WBRT groups respectively (p = 0.01). CONCLUSION: IORT as monotherapy in selected patients with EBC stands for an alternative option versus WBRT. It seems especially useful in advanced-age patients with severe comorbidities. IORT associates lesser early severe dermatitis.

Análisis de los factores radiopatológicos del cáncer de mama triple negativo y determinación de perfiles de riesgo / Analysis of the radio-pathological factors of triple negative breast cancer and determination of risk profiles

OBJETIVO: Los tumores triples negativos (TN) constituyen el subgrupo de cáncer de mama (CM) más agresivo. Nuestro objetivo es analizar los principales factores radiopatológicos de estos tumores para crear un perfil de riesgo. MATERIALES Y MÉTODOS: Es un estudio constituido por 140 pacientes diagnosticadas de CM TN desde enero del 2007 a diciembre del 2016. Se analizaron los factores radiológicos en resonancia magnética (RM) de estadificación: tamaño, necrosis, hallazgos asociados, adenopatías, parámetros de perfusión y difusión. En biopsias diagnósticas se estudiaron características del componente infiltrante: tipo histológico, Scarf-Bloom, Ki67 y p53 y el componente in situ. Se analizaron las adenopatías histológicamente positivas y en las piezas quirúrgicas: tamaño, invasión linfovascular/perineural y adenosis microglandular. El seguimiento finalizó en abril de 2018. Se evaluó la relación de los factores radiopatológicos con la recidiva y la supervivencia libre de enfermedad (SLE). RESULTADOS: Los tumores con tamaño igual o superior a 25 mm en RM, realce no nodular, edema mamario o retracción del complejo aréola-pezón y adenopatías presentaron más recidivas y menor SLE. Los carcinomas lobulillares infiltrantes, el tamaño posquirúrgico>20 mm y p53 <15% también se asociaron con la recidiva y una menor SLE. Las adenopatías histológicamente positivas se relacionaron con un mayor porcentaje de recidivas, y la invasión linfovascular, con una menor SLE. El análisis multivariante ha definido que el tamaño en RM>25 mm, el realce no nodular, las adenopatías en RM, y la expresión menor del 15% de p53 son variables pronósticas independientes. CONCLUSIONES: El tamaño igual o superior a 25 mm, realce no nodular y adenopatías en RM, y una expresión inferior al 15% de p53 condicionan una menor SLE

OBJECTIVE: Triple-negative tumors are the most aggressive type of breast cancer. We aimed to analyze the main radiologic and histopathologic factors of these tumors to create a risk profile. MATERIALS AND METHODS: We analyzed data from 140 patients diagnosed with triple-negative breast cancer between January 2007 and December 2016, with follow-up through April 2018. We analyzed the following variables in the breast MRI done for staging: size, necrosis, associated findings, adenopathies, and perfusion and diffusion parameters. We analyzed the following variables in histopathologic studies of biopsy specimens: histological type, Scarf-Bloom, Ki67, and p53 in the infiltrating component as well as in the in situ component. We analyzed the following variables in histopathologic studies of positive lymph nodes and surgical specimens: size, lymphovascular/perineural invasion, and microglandular adenosis. We analyzed the relation between the radiologic and histopathologic factors and recurrence and disease-free survival. RESULTS: MRI tumor size>25mm, non-nodular enhancement, breast edema, areola-nipple complex retraction, and lymph-node involvement were associated with recurrence and lower disease-free survival. Invasive lobular carcinoma, postsurgical size>20mm, and p53<15% were also associated with recurrence and lower disease-free survival. Histologically positive lymph nodes were associated with a greater percentage of recurrence and lymphovascular invasion and with lower disease-free survival. The multivariate analysis found that the variables MRI size>25mm, non-nodular enhancement, adenopathies on MRI, and p53 expression <15% were independent predictors of lower disease-free survival. CONCLUSIONS: In triple-negative breast tumors, factors associated with lower disease-free survival are non-nodular enhancement, size>25mm, and adenopathies on MRI, and p53 expression <15% on histopathologic study

Analysis of the radio-pathological factors of triple negative breast cancer and determination of risk profiles. / Análisis de los factores radiopatológicos del cáncer de mama triple negativo y determinación de perfiles de riesgo.

OBJECTIVE: Triple-negative tumors are the most aggressive type of breast cancer. We aimed to analyze the main radiologic and histopathologic factors of these tumors to create a risk profile. MATERIALS AND METHODS: We analyzed data from 140 patients diagnosed with triple-negative breast cancer between January 2007 and December 2016, with follow-up through April 2018. We analyzed the following variables in the breast MRI done for staging: size, necrosis, associated findings, adenopathies, and perfusion and diffusion parameters. We analyzed the following variables in histopathologic studies of biopsy specimens: histological type, Scarf-Bloom, Ki67, and p53 in the infiltrating component as well as in the in situ component. We analyzed the following variables in histopathologic studies of positive lymph nodes and surgical specimens: size, lymphovascular/perineural invasion, and microglandular adenosis. We analyzed the relation between the radiologic and histopathologic factors and recurrence and disease-free survival. RESULTS: MRI tumor size>25mm, non-nodular enhancement, breast edema, areola-nipple complex retraction, and lymph-node involvement were associated with recurrence and lower disease-free survival. Invasive lobular carcinoma, postsurgical size>20mm, and p53<15% were also associated with recurrence and lower disease-free survival. Histologically positive lymph nodes were associated with a greater percentage of recurrence and lymphovascular invasion and with lower disease-free survival. The multivariate analysis found that the variables MRI size>25mm, non-nodular enhancement, adenopathies on MRI, and p53 expression <15% were independent predictors of lower disease-free survival. CONCLUSIONS: In triple-negative breast tumors, factors associated with lower disease-free survival are non-nodular enhancement, size>25mm, and adenopathies on MRI, and p53 expression <15% on histopathologic study.

Análisis de los factores radio-patológicos y terapéuticos del cáncer de mama triple negativo y su influencia en la recidiva y supervivencia libre de enfermedad / Analysis of the radiopathological and therapeutic factors in triple-negative breast cancer and their influence on relapse and disease-free survival

Objetivo. Analizar la asociación entre la densidad mamográfica, la invasión linfovascular, la adenosis microglandular y el estado ganglionar de los tumores triples negativos (TN) con la recidiva tumoral y la supervivencia libre de enfermedad. Estudiar si la perfusión tumoral en las RM de estadificación se correlaciona con la recidiva tumoral, la supervivencia libre de enfermedad o los valores de restricción a la difusión. Analizar si la administración de quimioterapia neoadyuvante (QTN) o el tipo de tratamiento quirúrgico (cirugía conservadora o mastectomía) se asocian a un peor pronóstico. Pacientes y métodos. Estudio retrospectivo de las mamografías y de las RM pretratamiento de 122 pacientes con tumores TN entre los años 2007 y 2014. Se valoró la densidad mamaria en estudios mamográficos realizados en el momento del diagnóstico. El estado ganglionar se analizó en muestras de biopsia o quirúrgicas, mientras que la invasión linfovascular y la adenosis microglandular se estudió únicamente en muestras quirúrgicas. Resultados. La densidad mamográfica y los factores anatomo-patológicos no se asociaron con la recidiva tumoral. Los valores de realce máximo en la secuencia dinámica eran más altos en las pacientes sin recidiva tumoral (p=0,028), sin demostrar relación con la restricción a la difusión. Conclusiones. Los tumores con valores más altos de realce interno en RM de estadificación presentan un menor índice de recidivas. No se demostró correlación entre los valores de realce interno tumoral y de restricción a la difusión. Y no se observó asociación pronóstica con el resto de factores radio-patológicos (AU)

Objective. To analyse the association between breast density, lymphovascular invasion, microglandular adenosis and the axillary node status of triple-negative tumours (TN) with tumour recurrence and disease-free survival. To study whether tumour perfusion in MRI staging correlates with tumour recurrence, disease-free survival or diffusion restriction. To analyse whether the administration of neoadjuvant chemotherapy (NC) or the type of surgical treatment (breast-conserving surgery or mastectomy) are associated with a worse prognosis. Patients and methods. A retrospective study of mammograms and staging MRIs was performed from 2007 to 2014, including 122 women with TN breast cancer. Breast density was assessed in mammographic studies performed at the time of diagnosis. Lymph node status was analysed in biopsy or surgical specimens, whereas lymphovascular invasion and microglandular adenosis were studied only in surgical specimens. Results. Breast density and histopathological factors were not associated with tumour recurrence. The maximum enhancement values in the dynamic sequence were higher in patients without tumour recurrence (P=.028), without demonstrating a relationship with diffusion restriction. Conclusions. Tumours with higher values of internal enhancement showed less tumour recurrence. There was no correlation between the values of internal tumour enhancement and diffusion restriction. No prognostic association was observed with the remaining radiopathological factors (AU)

Factores pronósticos de respuesta a quimioterapia mediante RM en tumores triple negativos / Prognostic factors of chemotherapy response at MRI in triple-negative tumours

Objetivo. Analizar si la perfusión y restricción a la difusión de los tumores triple negativos en la resonancia magnética de estadificación se correlacionan con la respuesta a la quimioterapia neoadyuvante (QTN). Correlacionar la respuesta radiopatológica a la QTN y estudiar si el grado de respuesta asocia un peor pronóstico. Pacientes y métodos. Estudio retrospectivo de 73 pacientes con tumores triple negativos diagnosticados entre los años 2007 y 2014 con resonancia magnética de estadificación y de control posterior al tratamiento QTN. Se valoró el grado de respuesta radiológica al tratamiento QTN mediante resonancia magnética y la respuesta patológica en muestras quirúrgicas, siendo posible la correlación radiopatológica en 46 pacientes. Resultados. Se determinó moderada concordancia radiopatológica a la respuesta quimioterápica (kappa=0,590). Los tumores con un menor time to peak asociaban porcentajes mayores de respuesta radiológica completa (p=0,022) y los tumores con curvas funcionales tipo 3 se asociaban a mayores porcentajes de respuesta completa patológica (p=0,024). Se demostró menor supervivencia en las pacientes con menor respuesta radiológica (p=0,004) o patológica (p=0,04). No se encontró correlación entre los grupos de respuesta completa radiopatológica respecto al resto de grupos de respuesta y la supervivencia libre de enfermedad. Conclusiones. Los tumores triple negativos con menor time to peak o con curvas tipo 3 presentaban mejor respuesta al tratamiento. Se ha demostrado mayor supervivencia en tumores con mayor grado de respuesta radiopatológica (AU)

Objectives. To analyse whether perfusion and diffusion restriction in staging magnetic resonance imaging of triple-negative tumours correlate with response to neoadjuvant chemotherapy (NC). To correlate the radio-pathological chemotherapy response and determine whether the response is associated with a worse prognosis. Patients and methods. Retrospective study of 73 patients with triple-negative tumours diagnosed between 2007 and 2014 with staging magnetic resonance imaging and follow-up magnetic resonance imaging after NC treatment. The radiological response to NC treatment at magnetic resonance imaging and the pathological response in surgical specimens were assessed. Radio-pathological correlation was feasible in only 46 patients. Results. A moderate radiological-pathological concordance was found in relation to chemotherapy response (kappa=0.590). Tumours with lower time to peak of radiological complete response (P=.022) and tumours with functional type 3 curves were associated with higher percentages of pathological complete response (P=.024). Lower survival was demonstrated in patients with lower radiological (P=.004) or pathological (P=.04) response. No correlation was found between the complete radio-pathological response groups with respect to the rest of the response groups and disease-free survival. Conclusions. Triple-negative N tumours with lower time to peak or type 3 curves showed better response to treatment. Increased survival was found in tumours with a higher level of radio-pathological response (AU)

Papel de la resonancia magnética de mama en la valoración de la respuesta a la neoadyuvancia / Role of breast magnetic resonance imaging in assessing response to neoadjuvant therapy

La clasificación molecular del cáncer de mama ha permitido predecir su comportamiento biológico, proporcionando información de importancia diagnóstica y terapéutica. El desarrollo de esquemas específicos en terapia primaria sistémica ha aumentado el porcentaje de cirugías conservadoras, manteniendo unas tasas de supervivencia libre de enfermedad y supervivencia global equivalentes a las de la terapia adyuvante. En este ámbito, la resonancia magnética mamaria se ha consolidado como la técnica de imagen de elección para la valoración de la respuesta del cáncer de mama tratado con terapia primaria sistémica, presentando una buena correlación radiopatológica y con capacidad para discriminar diferentes niveles de respuesta en función del perfil molecular (AU)

Molecular classification of breast cancer has allowed us to predict its biological behaviour, providing important diagnostic and therapeutic information. The development of specific treatments in primary systemic therapy has increased the percentage of conservative surgery, with disease-free survival and overall survival rates equivalent to adjuvant therapy. In this setting, breast magnetic resonance imaging has become the imaging modality of choice to evaluate the response of breast cancer treated with primary systemic therapy. This technique has a good radiologic-pathologic correlation and allows discrimination of different types of response according to the molecular profile (AU)

La resonancia magnética en el cáncer de mama: un camino no invasivo hacia un horizonte pronóstico / Magnetic resonance imaging in breast cancer: a noninvasive road to prognosis

No disponible

Angiosarcoma primario de mama: utilidad de la resonancia magnética / Primary angiosarcoma of the breast: use of magnetic resonance imaging

Se expone el caso de una mujer de 46 años, que acude a la consulta por asimetría mamaria y masa palpable a la exploración. Se realizó mamografía, ecografía, PAAF/BAG, que se complementó con resonancia magnética (RM) (secuencias turbo-spin eco potenciadas en T2 y estudio dinámico 3D con secuencia SPGE potenciada en T1 con contraste paramagnético extracelular). En la RM el tumor presentó una estructura heterogénea muy aproximada al aspecto macroscópico de la lesión, y la RM aportó información sobre el comportamiento funcional. Se presentan las características morfológicas y el estudio funcional de la lesión, así como la correlación entre las distintas técnicas de imagen y el estudio anatomopatológico

We present the case of a 46 year old woman who comes to the consultation due to mammary asymmetry and palpable mass on examination. We performed a mammography, ultrasonography, FNAP/core biopsy, completing it with magnetic resonance imaging (MRI) (T2 weighted turbo-spin sequences and 3D dynamic study with a T1 weighted SPGE sequence with extracellular paramagnetic contrast). In the MRI, the tumor showed a heterogeneous structure that was close to the macroscopic aspect of the lesion, the MRI supplying information on the functional behavior. We present the morphological characteristics and functional study of the lesion and the correlation between the different imaging techniques and the pathology study